Effects of repeated oral doses of ketoconazole on a sequential ascending single oral dose of fedratinib in healthy subjects

Fedratinib—a JAK2 inhibitor approved for treatment of patients with intermediate-2 or high-risk primary or secondary myelofibrosis—may interact with antifungal ketoconazole, according to results from an open-label, fixed-sequence, cross-over study of patients receiving either 50 mg and 300 mg of fedratinib. In the analysis, fedratinib exposure increased more than 3-fold when coadministered with the antifungal among patients receiving either dose of fedratinib.